• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

食管癌患者接受放化疗后并发心包积液的风险因素。

Risk factors for pericardial effusion in patients with stage I esophageal cancer treated with chemoradiotherapy.

机构信息

Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan

Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.

出版信息

Anticancer Res. 2014 Dec;34(12):7389-93.

PMID:25503178
Abstract

AIM

We investigated clinical and dosimetric factors influencing the risk of developing pericardial effusion (PCE) in patients with Stage I esophageal cancer undergoing definitive chemoradiotherapy.

PATIENTS AND METHODS

Sixty-nine patients with Stage I esophageal cancer who underwent definitive chemoradiotherapy were retrospectively analyzed. Treatment comprised of three-dimensional conformal radiotherapy (60 Gy in 30 fractions) with concurrent chemotherapy. Clinical and dosimetric factors associated with PCE development were analyzed.

RESULTS

The median follow-up was 37 months (range=8-111 months); the crude PCE incidence rate was 52.2%. Grade 2 and 3 incidence rate was 47.8% and 4.3%, respectively. The median time to PCE onset was 5.7 months after radiotherapy. In multivariate analysis, pericardial V30 ≥ 41.6%, age ≥ 66 years, body mass index (BMI) ≥ 19 and diabetes mellitus (DM) were significant predictors of developing PCE.

CONCLUSION

The present study suggests that higher pericardial V30, advanced age, high BMI and DM are risk factors for developing PCE.

摘要

目的

我们研究了影响接受根治性放化疗的 I 期食管癌患者发生心包积液(PCE)风险的临床和剂量学因素。

患者和方法

回顾性分析了 69 例接受根治性放化疗的 I 期食管癌患者。治疗包括三维适形放疗(60 Gy,30 次)联合化疗。分析了与 PCE 发展相关的临床和剂量学因素。

结果

中位随访时间为 37 个月(范围=8-111 个月);粗 PCE 发生率为 52.2%。2 级和 3 级发生率分别为 47.8%和 4.3%。放疗后 PCE 发病的中位时间为 5.7 个月。多因素分析显示,心包 V30≥41.6%、年龄≥66 岁、BMI≥19 和糖尿病(DM)是发生 PCE 的显著预测因素。

结论

本研究表明,较高的心包 V30、较高的年龄、较高的 BMI 和 DM 是发生 PCE 的危险因素。

相似文献

1
Risk factors for pericardial effusion in patients with stage I esophageal cancer treated with chemoradiotherapy.食管癌患者接受放化疗后并发心包积液的风险因素。
Anticancer Res. 2014 Dec;34(12):7389-93.
2
Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy.接受根治性放化疗的不可切除食管癌患者发生心包积液的危险因素。
Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):707-14. doi: 10.1016/j.ijrobp.2007.10.056. Epub 2008 Jan 11.
3
Predictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy.在接受放化疗的食管癌患者中,通过心脏剂量-体积直方图分析确定的心包积液预测因素。
Br J Radiol. 2015 Feb;88(1046):20140168. doi: 10.1259/bjr.20140168. Epub 2014 Nov 27.
4
Pericardial effusion after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal cancer.食管癌根治性同步化疗和调强放疗后的心包积液。
Radiat Oncol. 2020 Feb 27;15(1):48. doi: 10.1186/s13014-020-01498-3.
5
Dosimetric predictors of radiation-induced pericardial effusion in esophageal cancer.食管癌放疗所致心包积液的剂量学预测因素
Strahlenther Onkol. 2017 Jul;193(7):552-560. doi: 10.1007/s00066-017-1127-8. Epub 2017 Apr 19.
6
Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients.食管癌患者放化疗后出现有症状的心包积液。
Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):487-93. doi: 10.1016/j.ijrobp.2013.07.008. Epub 2013 Aug 20.
7
Risk factors for pericardial effusion after chemoradiotherapy for thoracic esophageal cancer-comparison of four-field technique and traditional two opposed fields technique.胸段食管癌放化疗后心包积液的危险因素——四野技术与传统两野对穿技术的比较
J Radiat Res. 2018 May 1;59(3):291-297. doi: 10.1093/jrr/rry029.
8
Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer.食管癌放疗方式对心包和胸腔积液及生存影响的贝叶斯回归分析
Radiother Oncol. 2016 Oct;121(1):70-74. doi: 10.1016/j.radonc.2016.08.005. Epub 2016 Aug 22.
9
Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy.三维适形放疗治疗肺癌患者急性食管毒性的剂量-体积参数
Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):995-1002. doi: 10.1016/j.ijrobp.2004.12.025.
10
Clinical and dosimetric risk factors of acute esophagitis in patients treated with 3-dimensional conformal radiotherapy for non-small-cell lung cancer.三维适形放疗治疗非小细胞肺癌患者急性食管炎的临床和剂量学危险因素。
Am J Clin Oncol. 2010 Jun;33(3):271-5. doi: 10.1097/COC.0b013e3181a879e0.

引用本文的文献

1
Clinical outcomes and prognostic factors of volumetric modulated arc therapy (VMAT) of esophageal cancer.食管癌容积调强弧形放疗(VMAT)的临床疗效及预后因素
Rep Pract Oncol Radiother. 2024 Oct 3;29(4):426-436. doi: 10.5603/rpor.101529. eCollection 2024.
2
Heart is a heavy burden: cardiac toxicity in radiation oncology.心脏是一个沉重的负担:放射肿瘤学中心脏毒性。
Support Care Cancer. 2024 Nov 4;32(11):769. doi: 10.1007/s00520-024-08949-7.
3
Pericardial effusion in oncological patients: current knowledge and principles of management.
肿瘤患者的心包积液:当前认知与管理原则
Cardiooncology. 2024 Feb 16;10(1):8. doi: 10.1186/s40959-024-00207-3.
4
Past, Present, and Future of Radiation-Induced Cardiotoxicity: Refinements in Targeting, Surveillance, and Risk Stratification.辐射诱发心脏毒性的过去、现在与未来:靶向治疗、监测及风险分层的优化
JACC CardioOncol. 2021 Sep 21;3(3):343-359. doi: 10.1016/j.jaccao.2021.06.007. eCollection 2021 Sep.
5
Case report of simultaneous presentation of pulmonary embolism and pericardial effusion following an oncological esophagectomy.肿瘤性食管切除术后同时出现肺栓塞和心包积液的病例报告。
Int J Surg Case Rep. 2020;77:252-255. doi: 10.1016/j.ijscr.2020.10.090. Epub 2020 Oct 28.
6
Pericardial effusion after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal cancer.食管癌根治性同步化疗和调强放疗后的心包积液。
Radiat Oncol. 2020 Feb 27;15(1):48. doi: 10.1186/s13014-020-01498-3.
7
Analysis of cardiac toxicity after definitive chemoradiotherapy for esophageal cancer using a biological dose-volume histogram.应用生物剂量-体积直方图分析食管癌根治性放化疗后的心脏毒性
J Radiat Res. 2020 Mar 23;61(2):298-306. doi: 10.1093/jrr/rraa001.
8
Radiation-Associated Pericardial Disease.放射性心包疾病。
Curr Cardiol Rep. 2019 Jul 27;21(9):97. doi: 10.1007/s11886-019-1192-y.
9
Cardiovascular Complications Associated with Mediastinal Radiation.与纵隔放疗相关的心血管并发症
Curr Treat Options Cardiovasc Med. 2019 Jun 4;21(7):31. doi: 10.1007/s11936-019-0737-0.
10
The heart's exposure to radiation increases the risk of cardiac toxicity after chemoradiotherapy for superficial esophageal cancer: a retrospective cohort study.心脏暴露于辐射会增加表浅食管癌化放化疗后心脏毒性的风险:一项回顾性队列研究。
BMC Cancer. 2019 Mar 4;19(1):195. doi: 10.1186/s12885-019-5421-y.